5 news items
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
SAVA
10 May 24
. About Cassava Sciences, Inc.Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission
Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution
SAVA
8 May 24
distribution. "We are grateful to so many shareholders who continue to show support for Cassava Sciences and its mission
Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ
SAVA
1 May 24
Cassava Sciences, Inc.Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission
Redemption Date Announced for Warrants
SAVA
15 Apr 24
Sciences, Inc.Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
SAVA
25 Mar 24
biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer's disease. Our novel science
- Prev
- 1
- Next